LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Kodu・Aktsiate loetelu・MediciNova Inc

MediciNova Inc

Suletud

SektorTervishoid

1.31

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.28

Max

1.32

Põhinäitajad
By Trading Economics
Sissetulek	216K -2.6M
Müük	35K 187K
Aktsiakasum	-0.05
Kasumimarginaal	-1,383.144
Töötajad	6
EBITDA	63K -2.8M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+506.06% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-2M 67M
Eelmine avamishind	1.31
Eelmine sulgemishind	1.31

Uudiste sentiment

By Acuity

26%

74%

59 / 344 Pingereas Healthcare

MediciNova Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. juuni 2026, 21:51 UTC

Suurimad hinnamuutused turgudel

Merlin Shares Rally After Defense Department's Design Review Wraps

4. juuni 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4. juuni 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4. juuni 2026, 23:42 UTC

Omandamised, ülevõtmised, äriostud

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4. juuni 2026, 23:41 UTC

Omandamised, ülevõtmised, äriostud

Energy Resources of Australia to Enter Trading Halt

4. juuni 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4. juuni 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. juuni 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4. juuni 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4. juuni 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4. juuni 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4. juuni 2026, 20:44 UTC

Omandamised, ülevõtmised, äriostud

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4. juuni 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4. juuni 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4. juuni 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4. juuni 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4. juuni 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4. juuni 2026, 18:47 UTC

Omandamised, ülevõtmised, äriostud

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4. juuni 2026, 18:38 UTC

Tulu

Money Quote: Tech Weakness in Context -- WSJ

4. juuni 2026, 18:24 UTC

Tulu

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4. juuni 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4. juuni 2026, 16:58 UTC

Tulu

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4. juuni 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4. juuni 2026, 16:38 UTC

Tulu

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4. juuni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4. juuni 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4. juuni 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4. juuni 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4. juuni 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Võrdlus sarnastega

Hinnamuutus

MediciNova Inc Prognoos

Hinnasiht

By TipRanks

506.06% tõus

12 kuu keskmine prognoos

Keskmine 8 USD 506.06%

Kõrge 10 USD

Madal 6 USD

Põhineb 2 Wall Streeti analüütiku instrumendi MediciNova Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi MediciNova Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

59 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.